| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Alexander H. Stegh | |
| Fotini M. Kouri | |||
| Samuel A. Jensen | |||
| P2860 | cites work | Glioma oncoprotein Bcl2L12 inhibits the p53 tumor suppressor | Q24299628 |
| A stapled BID BH3 helix directly binds and activates BAX | Q24307663 | ||
| Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade | Q24311006 | ||
| Overexpression of bax in human glioma cell lines. | Q54080419 | ||
| Expression of bcl-2 in small cell lung carcinoma cells. | Q54218040 | ||
| Expression of antisense bcl-2 cDNA abolishes tumorigenicity and enhances chemosensitivity of human malignant glioma cells. | Q55472578 | ||
| BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma | Q73555358 | ||
| EGFR-dependent downregulation of Bim in epithelial cells requires MAPK and PKC-delta activities | Q83045380 | ||
| Necrotic death as a cell fate | Q36359618 | ||
| The prognostic influence of bcl-2 in malignant glioma | Q36644672 | ||
| A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo | Q36647747 | ||
| Bcl2L12-mediated inhibition of effector caspase-3 and caspase-7 via distinct mechanisms in glioblastoma | Q36825199 | ||
| Cancer stem cells and glioma | Q37217237 | ||
| Homeostatic functions of BCL-2 proteins beyond apoptosis | Q37797382 | ||
| The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy | Q37854419 | ||
| MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity | Q39679824 | ||
| BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer | Q39726300 | ||
| Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins | Q39956386 | ||
| Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion | Q40033557 | ||
| A role for proapoptotic BID in the DNA-damage response | Q40381562 | ||
| Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis | Q40511321 | ||
| BCL-2 family proteins modulate radiosensitivity in human malignant glioma cells | Q40738665 | ||
| Inhibition of virus-induced neuronal apoptosis by Bax. | Q40943846 | ||
| BH3-triggered structural reorganization drives the activation of proapoptotic BAX. | Q41884328 | ||
| BAK alters neuronal excitability and can switch from anti- to pro-death function during postnatal development | Q44399624 | ||
| Proapoptotic BID is an ATM effector in the DNA-damage response | Q46669145 | ||
| The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. | Q46970879 | ||
| What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator | Q48939992 | ||
| Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 | Q24651548 | ||
| Bcl2L12 inhibits post-mitochondrial apoptosis signaling in glioblastoma | Q24670606 | ||
| MicroRNAs: genomics, biogenesis, mechanism, and function | Q27861070 | ||
| Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3 | Q28246420 | ||
| The mitochondrial death squad: hardened killers or innocent bystanders? | Q28276624 | ||
| Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics | Q28469345 | ||
| BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations | Q28756824 | ||
| The BCL-2 protein family: opposing activities that mediate cell death | Q29547380 | ||
| Malignant gliomas in adults | Q29615708 | ||
| Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis | Q29619677 | ||
| Molecular cloning, physical mapping, and expression analysis of a novel gene, BCL2L12, encoding a proline-rich protein with a highly conserved BH2 domain of the Bcl-2 family | Q30168116 | ||
| Bcl-2 expression in higher-grade human glioma: a clinical and experimental study | Q30321045 | ||
| Adenoviral natural born killer gene therapy for malignant glioma | Q33188372 | ||
| 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. | Q33266778 | ||
| Gossypol treatment of recurrent adult malignant gliomas | Q33329763 | ||
| Notch3 cooperates with the EGFR pathway to modulate apoptosis through the induction of bim. | Q33618246 | ||
| Functional delivery of siRNA in mice using dendriworms | Q33686651 | ||
| The WHO classification of tumors of the nervous system | Q33845646 | ||
| EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity. | Q33872371 | ||
| The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry | Q33887183 | ||
| A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications | Q33900952 | ||
| STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma | Q33903747 | ||
| Cell death | Q34019760 | ||
| Inhibition of brain tumor growth by intravenous poly(β- l -malic acid) nanobioconjugate with pH-dependent drug release | Q34241230 | ||
| Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses | Q34393758 | ||
| Beyond effector caspase inhibition: Bcl2L12 neutralizes p53 signaling in glioblastoma | Q34621019 | ||
| Downregulations of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG. | Q34997130 | ||
| The CD95(APO-1/Fas) DISC and beyond | Q35091401 | ||
| Bcl-2 promotes malignant progression in a PDGF-B-dependent murine model of oligodendroglioma. | Q35388292 | ||
| BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy | Q35454275 | ||
| Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin | Q35763574 | ||
| Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases | Q36097402 | ||
| New approaches and therapeutics targeting apoptosis in disease | Q36138109 | ||
| Investigations on gossypol: past and present developments | Q36300043 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | brain tumor | Q233309 |
| bcl-2 family | Q554446 | ||
| glioma | Q1365309 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 838916 | |
| P577 | publication date | 2012-01-01 | |
| 2012-02-14 | |||
| P1433 | published in | The Scientific World Journal | Q7762585 |
| P1476 | title | The role of Bcl-2 family proteins in therapy responses of malignant astrocytic gliomas: Bcl2L12 and beyond | |
| P478 | volume | 2012 |
| Q58700451 | Adjuvant Therapy Using Mistletoe Containing Drugs Boosts the T-Cell-Mediated Killing of Glioma Cells and Prolongs the Survival of Glioma Bearing Mice |
| Q38973191 | Aplysin enhances temozolomide sensitivity in glioma cells by increasing miR-181 level |
| Q34517100 | Cellular and molecular mechanisms underlie the anti-tumor activities exerted by Walterinnesia aegyptia venom combined with silica nanoparticles against multiple myeloma cancer cell types. |
| Q60302022 | Clinical significance and effect of MTDH/AEG-1 in bladder urothelial cancer: a study based on immunohistochemistry, RNA-seq, and in vitro verification |
| Q38101608 | Enhancing radiation therapy for patients with glioblastoma |
| Q37382513 | Estrogen receptor β isoform 5 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis through interaction with Bcl2L12. |
| Q39291616 | Gliomatosis cerebri type 1 with extensive involvement of the spinal cord and BRAF V600E mutation |
| Q40511892 | Optimized mixture of As, Cd and Pb induce mitochondria-mediated apoptosis in C6-glioma via astroglial activation, inflammation and P38-MAPK. |
| Q37641600 | Predicting the cell death responsiveness and sensitization of glioma cells to TRAIL and temozolomide |
| Q90401877 | Proteinase-activated receptor-2 enhances Bcl2-like protein-12 expression in lung cancer cells to suppress p53 expression |
| Q35653078 | Silence of MACC1 expression by RNA interference inhibits proliferation, invasion and metastasis, and promotes apoptosis in U251 human malignant glioma cells |
| Q42968961 | The ER stress inducer DMC enhances TRAIL-induced apoptosis in glioblastoma. |
Search more.